Table 1.
Cardiovascular complications of coronavirus disease 2019 (COVID-19) vaccines.
| Vaccine | Data source or region | Time | Complication | Total number administered | Number of events | Complication rate |
|---|---|---|---|---|---|---|
| BNT162B2 (8) | Israel | To 2021.3.24 | Myocarditis | More than 4 million | 6 | 1.5/1 million |
| BNT162B2 (13) | MHRA | 2020.12.9–2021.5.26 | Thrombosis | 10.6 million | 33 | 3.11/1 million |
| BNT162B2 (13) | Singapore | To 2021.5.31 | Thrombosis | 1,766,493 | 3 | 1.70/1 million |
| BNT162B2 (14) | EMA | Unknown | Thrombosis | 54 million | 35 | 0.65/1 million |
| mRNA vaccine (19) | VAERS | To 2021.2.2 | ITP | 20 million | 20 | 1.00/1 million |
| BNT162B2 (18) | Israel | 2021.2–2021.3 | ATTP | 5 million | 4 | 0.80/1 million |
| mRNA vaccine (4) | DUMC | 2021.2.1–2021.4.30 | Myocarditis | 561,197 | 4 | 7.14/1 million |
| mRNA vaccine (9) | USA | 2020.12.29–2021.6.1 | Myocarditis | 52 million | 1,226 | 23.58/1 million |
| mRNA-1273 (14) | EMA | Unknown | Thrombosis | 4 million | 5 | 1.25/1 million |
| mRNA vaccine and ChAdOx1 (13) | VigiBase | 2020.12.12–2021.3.16 | Thrombosis | Unknown | 2,169 | Unknown |
| ChAdOx1 (1) | PRAC | To 2021.4.7 | Thrombotic thrombocytopenia | 34 million | 222 | 6.53/1 million |
| ChAdOx1 (21) | UK | To 2021.4.14 | Thrombotic thrombocytopenia | 21.2 million | 168 | 7.92/1 million |
| AD26.COV2·S (21) | USA | To 2021.4.13 | Thrombosis | 6.8 million | 15 | 2.21/1 million |
| AD26.COV2·S (14) | EMA | Unknown | Thrombosis | More than 7 million | 6 | 0.86/1 million |
MHRA, Medicines and Healthcare Products Regulatory Agency of the United Kingdom; EMA, European Medicines Agency; VAERS, Vaccine Adverse Events Reporting System; DUMC, Duke University Medical Center; VigiBase, WHO Global Database for Individual Case Safety Reports; PRAC, the EMA's Pharmacovigilance Risk Assessment Committee.